Expansion of IOA-244 Trial Fully Enrolled for Uveal Melanoma

Source: Cure Today, November 2021

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

In early November, iOnctura SA announced it has fully enrolled an expansion group of patients with metastatic uveal melanoma in the DIONE-01 study. The trial is focused on examining the selective PI3K? inhibitor IOA-244.

The study is comprised of two parts, with part A being complete. In part A, the researchers analyzed the safety, tolerability and dosage of IOA-244 in patients. Part B will look at expansion groups of patients with different tumor types, including those within the metastatic uveal melanoma group. It will determine whether IOA-244 increases anti-tumor immune responses in patients – as monotherapy or in combination with pemetrexed/cisplatin and an immune checkpoint inhibitor.

Up to 182 patients with uveal melanoma, cutaneous melanoma, non-small cell lung cancer, mesothelioma, myelofibrosis or non-Hodgkin lymphoma will be enrolled. There will be up to 26 patients with metastatic uveal melanoma recruited to determine monotherapy activity of IOA-244.

READ THE ORIGINAL FULL ARTICLE